Therapy Areas: Oncology
EU approves AstraZeneca's Etcamah combination for 1st-line ER-positive advanced breast cancer
23 July 2026 - Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) announced on Thursday it has secured European Union approval for Etcamah (camizestrant) combined with a CDK4/6 ...
BeOne Medicines expands US manufacturing with USD300m investment
23 July 2026 - Oncology company BeOne Medicines Ltd (NASDAQ:ONC) (HKEX:06160) (SSE:688235) announced on Thursday that it will invest USD300m to expand its flagship manufacturing and research and devel...
GSK's Jideytro (zidesamtinib) gains US approval for previously treated ROS1-positive NSCLC
23 July 2026 - Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) announced on Wednesday that the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhib...
Greenwich LifeSciences secures UK approval to expand Phase III breast cancer trial
22 July 2026 - US biopharmaceutical company Greenwich LifeSciences, Inc. (NASDAQ: GLSI) said on Wednesday it has received regulatory clearance to extend its Phase III FLAMINGO-01 trial into the United...
Elephas Biosciences partners with Invitrocue to promote elive platform in Singapore and Malaysia
22 July 2026 - Elephas Biosciences Corporation, developer of an innovative live tissue platform for immunotherapy response prediction, announced on Tuesday that it has entered into an international pa...
Lupin spins out two oncology programmes to Kaveri Therapeutics
21 July 2026 - India-based global pharmaceutical company Lupin Limited (BSE: 500257) (NSE: LUPIN) announced on Tuesday the strategic spin-out of two oncology programmes, LNP7457 (PRMT5) and LNP8701 (S...